American investigation into Germany’s drug pricing is about more than medicine. It is an early test of how far the Turnberry agreement can stretch when US pressure meets European domestic politics.
Two days after the European Parliament ratified the EU–US trade deal, the United States opened a Section 301 investigation into Germany’s drug-pricing laws. While formally within the agreement’s 15 percent tariff ceiling for now, the US is already pushing against the premise of the deal.
On June 18, US Trade Representative Jamieson Greer announced a self-initiated Section 301 investigation into what his office called Germany’s “persistent underpayment for innovative pharmaceutical products”.
The investigation came from USTR’s own motion rather than in response to an industry petition — meaning the government chose, on its own initiative, to open the front. It will accept comments through August 10, leading to a hearing on September 22, with a decision only after. That is when Washington can impose tariffs on German pharma exports, revoke concessions, or push Berlin into a bilateral deal.
You might be interested
The American grievance
Greer’s case rests on a real phenomenon: US patients pay between three and four times what other wealthy countries do for brand-name drugs. RAND Corporation puts the gap at 4.22 times on a net basis, and the US government’s own analysis puts US branded prices at 344 percent of those abroad.
From there Greer makes a larger leap — that this gap leaves America subsidizing a disproportionate share of global pharmaceutical R&D, and that German price controls suppress what the market would otherwise pay.
The truth is more structural. European governments negotiate prices directly, usually as the dominant buyer, and use cost-effectiveness assessments to refuse premium prices for drugs that don’t outperform existing treatments. The US, by contrast, lets manufacturers set launch prices and until recently barred Medicare from negotiating at all.
What Greer calls “persistent underpayment” is what health economists call value-based pricing. Germany isn’t underpaying; it is declining to overpay — and the US gap is largely a product of its own choice not to bargain.
The catalyst
The trigger for the US investigation was a reform Berlin advanced in April to curb its healthcare spending, fast-tracking additional manufacturer discounts and rebates into the public insurance system. Greer called it a “serious step backwards.”
But Germany’s action was a domestic health-budget measure, not a trade barrier. The US is treating a sovereign spending decision as grounds for an unfair trade dispute.
The US pharma campaign
Last year Washington struck price-control deals with more than a dozen drugmakers, tying US prices to the lower benchmarks paid abroad — giving both the industry and the administration a reason to make Europe pay more. In April the UK agreed to spend billions more on innovative medicines over a decade in exchange for a three-year tariff reprieve. “Germany should follow suit,” Greer said.
Pfizer’s Albert Bourla wrote to Chancellor Friedrich Merz this month warning the reform could jeopardize the company’s German investments, according to German newspaper Handelsblatt.
The Turnberry risks
This complicates the deal as branded medicines fall under Turnberry’s 15 percent ceiling. For Europe, the question is now not whether tariffs will come, but at what level when they do. Anything above 15 percent risks breaking the deal.
Should the US exceed the agreement, the ratified deal does include safeguards enabling the European Commission to suspend it if Washington violates its side. The legislation implementing the agreement was formally approved by EU member states on Thursday.
“Unfortunately, this is no bad joke,” wrote MEP Bernd Lange on social media, who chairs the Parliament’s trade committee and pushed for those safeguards. “That is interference in national sovereignty. Absolute no-go! Good that the EP secured a safety net against Turnberry violations.”
The Commission, which would have to enact those safeguards, has been more cautious. “We are in touch with German authorities,” a spokesperson said, with a “clear expectation” that the US will uphold its commitments under the EU–US joint statement.
Berlin’s split message
German Chancellor Merz called drug pricing “a purely domestic matter” and said he assumes Washington will honor the deal, including its caps on pharmaceutical tariffs. In private, however, Germany may be following the UK’s footsteps: Health Minister Nina Warken confirmed this week that German officials have been holding talks with the US on pharmaceuticals, and the Bundestag vote was postponed, with changes to the rebate plans reportedly under consideration.
The public posture is sovereignty; the private behavior is negotiation.
Under American pressure, Germany’s choices have shrunk to a hard binary: resist and risk the deal, or concede and buy time. Quiet negotiation looks like the safe middle — but it is really just capitulation on a slower clock.
President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development,” Greer said. “Our trading partners need to step up and start paying their fair share.”
Ratified for a week, the EU–US deal is already shakier than the day it passed, and it has left Europe in a bind. Germany can capitulate—fold its drug-pricing reform, follow the UK, pay more—and call it sovereignty preserved. Or it can hold the line, let the US breach the 15 percent ceiling, and watch the deal it just ratified break apart.
The middle way, the one where Europe keeps its policies and keeps the deal, is the path that doesn’t seem possible for now. That is the trap: a deal whose terms can be honored to the letter and still be used to extract what was never in it. The only real question left is which way Europe would rather lose — and whether the Commission, if pushed, would ever actually pull the trigger the EP fought so hard to load.
